Evidence map›Paper›PMID 41531982›Full record

ArticleACS medicinal chemistry letters2026

Improving Anticancer Activity of Doxorubicin by 4'-

Anna A Griadunova, Nicholas L Petrone, Madeleine S Maker, Brian Pallares, Trevor Leung, Allison N Shim, Ömer H Yilmaz, Jacob M Goldberg, Jonathan Braverman, Fang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anna A GriadunovaInnovative Genomics Institute, University of California, Berkeley, Berkeley, California 94720, United States.ORCID https://orcid.org/0000-0002-5189-8530
Nicholas L PetroneDepartment of Chemistry, University of Rhode Island, Kingston, Rhode Island 02881, United States.
Madeleine S MakerInnovative Genomics Institute, University of California, Berkeley, Berkeley, California 94720, United States.ORCID https://orcid.org/0000-0003-3222-3607
Brian PallaresDepartment of Chemistry, Colgate University, Hamilton, New York 13346, United States.ORCID https://orcid.org/0009-0003-8651-7392
Trevor LeungInnovative Genomics Institute, University of California, Berkeley, Berkeley, California 94720, United States.ORCID https://orcid.org/0009-0005-0840-5381
Allison N ShimInnovative Genomics Institute, University of California, Berkeley, Berkeley, California 94720, United States.
Ömer H YilmazDepartment of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Jacob M GoldbergDepartment of Chemistry, Colgate University, Hamilton, New York 13346, United States.ORCID https://orcid.org/0000-0002-8004-3769
Jonathan BravermanInnovative Genomics Institute, University of California, Berkeley, Berkeley, California 94720, United States.
Fang WangDepartment of Chemistry, University of Rhode Island, Kingston, Rhode Island 02881, United States.ORCID https://orcid.org/0000-0002-9192-6858

Funding

Training CoreP20GM103430 · NIGMS · UNIVERSITY OF RHODE ISLAND · PI Bongsup P Cho · 2012 to 2026
$63.6M
NIGMS NIH HHS P20 GM103430
6 · The paper itself

Abstract

Efflux pump-mediated multidrug resistance is a common mechanism by which cancer cells reduce the efficacy of a broad range of small-molecule therapeutics. We discovered that substituting the 4'-hydroxy group of doxorubicina known efflux pump substratewith an

Indexed as

ABC transportersanthracyclinesanticancerdoxorubicindrug effluxmultidrug resistanceP-glycoprotein

Identifiers

PMID41531982
PMCPMC12794098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.